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Abstract
Myelodysplastic  syndromes  (MDSs)  are  heterogeneous  hematopoietic  disorders
associated with various degrees of myelosuppression and transformation into acute
leukemia.  Chromosome  7  abnormalities  occur  at  any  age,  have  several  disease
associations,  and  are  generally  associated  with  poor  outcome.  Treatment  of  the
associated disease conditions may have a positive impact on the outcome of certain
types of MDSs. For patients eligible for hematopoietic stem cell transplantation (HSCT),
allografts are the standard of care, while supportive measures and the use of hypome‐
thylating  agents,  such  as  5-azacytidine  and  decitabine,  constitute  the  mainstay  of
management in individuals who are not fit for allogeneic HSCT. However, the use of
hypomethylating agents in conjunction with allogeneic HSCT using nonmyeloabla‐
tive conditioning therapies may be an appealing therapeutic option for older patients
with comorbid medical conditions.
Keywords: myelodysplastic syndrome, monosomy 7, 5-azacytidine, decitabine, hema‐
topoietic stem cell transplantation
1. Introduction
MDSs are a heterogeneous group of clonal hematopoietic stem cell disorders characterized by
ineffective hematopoiesis, dysplastic changes in the peripheral blood and bone marrow (BM),
and a variable risk of progression into acute myeloid leukemia (AML) [1–4]. Primary MDS has
a bimodal age incidence. It is usually a disease of old age as more than 50% of patients are ≥70
years of age [5]. Primary MDS is less common in the pediatric population and it includes specific
pediatric syndromes such as juvenile chronic myeloid leukemia (JCML) and infantile monos‐
omy 7 syndrome [5].
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The clinical, pathologic, and cytogenetic features of primary MDS in younger patients appear
to be different from those in elderly individuals suggesting that this may represent a biologi‐
cally different disease [5]. In patients with MDS, with or without abnormal chromosomal
karyotype, the type and the quantity of the abnormal karyotype have clinical values in
predicting transformation to acute leukemia [6]. The use of granulocyte-monocyte colony
stimulating factor (GM-CSF) in congenital BM failure syndromes may induce or accelerate the
onset of leukemic transformation [7].
2. Pathogenetic mechanisms in MDSs
Several mechanisms are involved in the pathogenesis of MDSs and these include: (1) enhance‐
ment of a self-renewal of a hematopoietic stem cell or acquisition of self-renewal in a progenitor
cell, (2) enhancement of proliferative capacity in the disease-sustaining clone and/or in its more
differentiated progeny, (3) impairment or blockade of differentiation, (4) genetic or epigenetic
instability, (5) antiapoptotic mechanisms in the disease-sustaining cells, (6) evasion of the
immune system, and (7) suppression of normal hematopoiesis leading ultimately to BM failure
[8].
3. Epigenetics in MDSs
Epigenetics is the heritable alteration in gene expression without DNA sequence change. The
primary epigenetic modifiers are DNA methylation and histone modifications, both of which
are potentially reversible [9]. DNA methylation plays a major role in tissue- and stage-specific
gene regulation and it increases with age. Aberrant methylation of certain promoter regions
can occur in diseases particularly cancers and correlates with gene silencing [9]. Epigenetic
changes in the form of modification of the transcriptional capacity of the cell via processes such
as DNA methylation and histone deacetylation can also alter gene expression impacting
disease biology [10].
Advances in the science of epigenetics have led to better understanding of the specific
pathogenetic mechanisms underlying MDSs. DNA methylation provides a major epigenetic
code of lineage and development-specific genes that control expression of normal cells [8]. The
most relevant molecular mediators of the epigenetic state in MDS are gene expression patterns
maintained by methylation of cytosine residues in DNA and covalent modification of histones.
TET2 status may be a genetic predictor of response to azacytidine, independently of karyotype
and holds promise as one of the tools available to help in better selection of patients for
treatment [8].
Cancer is characterized by global DNA hypomethylation and regional promoter hyperme‐
thylation of genes [9, 10]. Promoter methylation of CDKN2B [encoding p15INK4b] has been
shown to be restricted to the malignant hematological disorders [9, 10]. Several tumor
suppressor genes (TSGs) are inactivated by promoter hypermethylation. Potentially reversible
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silencing of genes, such as CDKN2B, by promoter methylation has been shown to occur in
MDS and it increases with disease progression [9, 10].
1. Unknown etiology.
2. Old age; more than 50 years
3. Obesity
4. Alcohol intake
5. Tobacco use
6. Sweet's syndrome
7. Vitamin deficiency: B12 and folate
8. Infections: - Human immunodeficiency virus - Epstein-barr virus
- Tuberculosis - Brucellosis
9. Autoimmune disorders:
- Behcet syndrome
- Fibrosing alveolitis
- Systemic lupus erythromatosis
10. Exposure to: - Solvents - Lead
- Benzene - Arsenic
- Herbicides - Hair dyes
- Pesticides - Agricultural chemicals
11. Cytotoxic chemotherapy: - Alkylating agents - Topoisomerase Π inhibitors
12. Radiotherapy
13. Bone marrow failure syndromes: - Aplastic anemia - Fanconi anemia
- Dyskeratosis congenita - Diamond Blackfan syndrome
- Paroxysmal nocturnal hemoglobinuria
- Congenital neutropenia (Kostmann's syndrome)
14. Genetic, familial and hereditary
disorders:
- Ataxia telangiectasia - Trisomy 8 mosaicism
- Xeroderma pigmentosa - Down syndrome
- Bloom's syndrome - Neurofibromatosis
15. Miscellaneous:
- Polycythemia rubra vera
- Familial myelodysplastic syndromes;
monosomy 7
- Germ cell tumors (embryonal dysgenesis)
- Mutagen detoxification [ GSTq1 - null ]
- Family history of hematopoietic cancer
Table 1. .Etiology, risk factors and epidemiological associations of myelodysplastic syndromes.
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4. Etiology and associations of MDSs
MDSs have several etiologies, risk factors, and epidemiological associations as shown in
Table 1 [11–43]. Also, several hereditary diseases predispose to familial forms of MDS/AML
as shown in Table 2 [11, 16, 18, 23, 25, 27, 44–48].
4.1. Familial MDSs
Familial MDSs are rare diseases. The most common form of familial MDSs is familial platelet
disorder, caused by heterozygous germline RUNX1 mutations, which has the propensity to
evolve into myeloid malignancy. Many patients lack history of bleeding or thrombocytopenia
[44, 46, 47]. Several cases of T-acute lymphoblastic leukemia (ALL) have been reported in
patients with inherited RUNX1 mutations [44]. Novel causative mechanisms such as RUNX1
deficiency result in constitutional microdeletions of 21q22 and myelodysplasia associated with
telomerase deficiency [44]. Treatment of familial MDS is allogeneic hematopoietic stem cell
transplantation (HSCT) but donors have to be screened for deficiency of RUNX1 and deficiency
of telomerase [44].
The following genetic mutations have been described in familial MDS/AML: TERC, TERT,
CEBPA, GATA2, and RUNX1 [16, 44, 46–48].
4.2. MonoMac syndrome
MonoMac syndrome is a familial disorder associated with GATA2 deficiency, inherited as
autosomal dominant and causes early onset of MDS/AML [47, 48]. Additional acquisitions
include: monosomy 7 and ASXL1 mutations. Genetic mutations are detected in dendritic cells,
monocytes, natural killer (NK) cells and B-lymphocytes. Many carriers are asymptomatic. The
syndrome is associated with severe infectious complications and familial predisposition to
cancer. Aggressive therapeutic strategies are needed as the disease has poor outcome [47, 48].
GATA2 mutations have also been described in familial MDS/AML and Emberger syndrome
[46–48].
5. Cytogenetic abnormalities in MDSs
Chromosomal abnormalities are detectable in 40–60% of patients with de novo MDS and
approximately 90% of patients with secondary therapy-related MDSs (t-MDSs) [1]. The most
frequent cytogenetic abnormalities are del(5q), monosomy 7, del(7q), trisomy 8, complex
karyotype, and -Y [1]. Chromosome 5 and 7 abnormalities are considered to be the most
frequent recurrent genetic abnormalities in myeloid malignancies (MDS and AML) as they
occur in 10–20% of myeloid neoplasms [49].
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Pure familial MDS Familial MDS/AML
1. Familial monosomy 7
2. Chromosome 21q22 deletions
3. Telomere deficiency-associated familial MDS
[occult dyskeratosis congenita]
4. Familial platelet disorder with propensity to myeloid
malignancy
- Bone marrow failure syndromes:
1. Diamond-Blackfan syndrome
2. Severe congenital neutropenia
3. Congenital amegakaryocytic thrombocytopenia
4. Dyskeratosis congenita
5. Schwachman-Diamond syndrome
- DNA repair deficiency syndrome:
1. Fanconi anemia
2. Bloom syndrome
3. Li-Fraumeni syndrome
- Signal transductions:
1. Noonan syndrome
2. Neuorofibromatosis-1
- Numerical chromosomal abnormalities:
1. Trisomy 21
Abbreviations: MDS, myelodysplastic syndrome; AML, acute myeloid leukemia.
Table 2. Familial MDS/AML.
6. Chromosome 7 abnormalities
Abnormalities involving chromosome 7 occur in approximately 20% of patients with MDS
having clonal cytogenetic abnormalities. Abnormalities of chromosome 7 include: (1) total loss
of chromosome 7 [monosomy 7], (2) deletion of a segment of the long arm of chromosome 7
[del(7q)], and (3) translocations involving chromosome 7 [2]. However, these cytogenetic
anomalies have different prognostic significance [1, 2, 50, 51]. MDS with monosomy 7 has poor
prognosis, while isolated del (7q) has a better outcome compared to isolated monosomy 7 [2].
Del(7q) which has distinct clinical and pathological characteristics should no longer be
considered in the same prognostic category as monosomy 7 [2]. Also, the prognostic impact
of der(7) t(1,7) (q10 or p10) is less adverse once compared to monosomy 7 or del (7q) [1]. In a
series of 246 patients with myeloid disorders: monosomy 7 or -7 was the most frequent
chromosomal abnormality as it was reported in 51% of patients with secondary myeloid
disorders, del(7q) was found in 7% of cases, and partial monosomy was found in 8% of
secondary myeloid diseases, while in de novo myeloid disorders, monosomy 7 and del(7q) were
reported in only 10% of patients [52].
6.1. Disease associations
Chromosome 7 abnormalities are associated with: (1) de novo and t-MDS, (2) de novo and
therapy related AML (t-AML), (3) JCML, (4) juvenile myelomonocytic leukemia [JMML], (5)
familial monosomy 7, (6) primary myelofibrosis, (7) Down's syndrome, (8) Fanconi anemia,
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and (9) lymphoma [50, 51, 53]. Monosomy 7 is the commonest chromosomal abnormality in
all of the above conditions except in primary myelofibrosis, where del(7q) is the commonest
chromosome 7 anomaly [53]. In adults, chromosome 7 abnormalities are associated with: (1)
advanced age, (2) antecedent MDS, and (3) resistance to current therapies [54]. In patients with
MDS and AML, chromosome 7 abnormalities usually carry poor prognosis [54].
6.2. Genes on chromosome 7 and their detection
Genes that have been reported to have microdeletions involving chromosome 7q21.2-q21.3
include: SAMD9, SAMD9L, and HEPACAM2 [55]. The following acquired somatic deletions
have also been reported at chromosome 7q36.1: EZH2, CUL1, and TET2 [56, 57]. Examples of
additional genetic mutations that have been reported in monosomy 7 and del(7q) include:
ASXL1, RUNX1, CBL, ETV6, FAM40B, FAM115A, SEMA3A, LUC7L2, SSPO, NRCAM, GRM8,
HYAL4, RABL5, TRIM24, FISI, and CUX1 [51, 57, 58]. Chromosome 7 abnormalities can be
detected by conventional cytogenetics or interphase fluorescence in situ hybridization (FISH)
[59]. Interphase FISH is a very useful method in detecting -7/7q- in patients with MDS. Also,
it is more sensitive in detecting chromosome 7 abnormalities than conventional cytogenetics
[59]. Refined chromosomal analysis has emerged as a tool that has considerable impact on
decision making and development of treatment protocols in patients with MDS and AML [60].
6.3. The commonly deleted segments (CDSs)
Several studies on MDS and AML specimens with interstitial deletions on chromosome 7 have
implicated three putative CDSs at the following chromosome bands: 7q22, 7q34, and 7q35-36.
However, 7q22 is the most frequently deleted band in patients with MDS/AML having del(7q)
[3]. The following genes in monosomy 7/del(7q) MDS/AML have been reported to be inacti‐
vated or to harbor recurrent genetic mutations such as EZH2, LUC7L2, and CUX1 [3].
The CDS on the long arm of chromosome 7 between 7q22 and 7q36 has been identified to
harbor a number of haploinsufficient myeloid TSGs [49, 50, 54]. Loss of function of at least one
TSG contributes to disease progression and leukemogenesis or leukemic transformation [50,
54]. It is feasible to somatically delete a large chromosomal segment that is implicated in tumor
suppression in hematopoietic cell population in vitro [54]. The CDSs that occur at chromosomal
bands7q22, 7q34, and 7q35-q36 contain the following genes: TRIM24, SVOPL, ATP6V0A4,
TMEM213, KIAA1549, LUC7L2, KLRG2, CLEK2L, HIPK2, TBXAS1, ZC34AV1L, ZC3HAV1,
TTC26, UBN2, C7orf55, TPK1, CNTNAP2, MIR548F3, C7orf33, CUL1, and EZH2 [49].
Loss of TP53 is more frequently associated with del5q rather than del7q, while loss of ETV6 is
particularly associated with concurrent del(5q) and del(7q) [49]. CUX1, a gene encoding a
homeodomain-containing transcription factor, has been identified within the CDS on chro‐
mosome 7 (7q22.1) [61]. CUX1 is expressed at haploinsufficient levels in leukemias with
chromosome 7 abnormalities. Haploinsufficiency of CUX1 gave human hematopoietic cells a
significant engraftment advantage on transplantation in immunodeficient mice [61].
Monosomy 7 and del(7q) are highly recurrent chromosomal abnormalities in myeloid malig‐
nancies including: AML, de novo MDS, and t-MDS/AML [51, 54, 61]. Also, monosomy 7 and
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del(7q) are common findings in children and adults who develop MDS as a second malignant
neoplasm [27]. In t-MDS/AML with chromosome 7 abnormalities, the peak incidence is
between 3 and 7 years after cessation of cytotoxic chemotherapy such as alkylating agents [27].
Under such circumstances, monosomy 7 and del(7q) are not equivalent in prognosis and
spectrum of disease phenotype [51].
Monosomy 7 and del(7q) are highly prevalent in acquired cytogenetic abnormalities in de
novo MDS/AML and t-MDS/AML [3]. The proportion of -7/del (7q) cells is markedly increased
in hematopoietic stem cell (HSC) and progenitor cell compartments of MDS patients relative
to T and B lymphocytes [3]. Recent studies demonstrating quantitative changes in the fre‐
quencies of phenotypic primitive long-term HSCs, common myeloid progenitors, and
granulocyte-monocyte progenitors in MDS patients with -7/del(7q) further support the diverse
effects on hematopoiesis [3].
After many attempts, mice with 5A3 deletions in the CDS of chromosome band 7q22 have been
successfully generated [54]. The 5A3 deleted mice have shown normal hematologic parameters
but have not developed myeloid malignancies spontaneously [54]. Animal studies have also
shown that heterozygous 5A3 deletion does not accelerate the evolution of leukemia or
modulate the responsiveness to antileukemic drugs, while homozygous 5A3 deletions are
embryonically lethal [54].
The following 7q genes have been implicated in contributing to leukemogenesis by haploin‐
sufficiency or epigenetic transcriptional repression: SAMD9L, RASA4, dedicator of cytokinesis
4 (DOCK4), and MLL3 [3]. Animal studies have shown that the long-term HSC compartment
is expanded in 5A3+/del mice and that the 5A3 deletion partially rescues defective repopulation
in GATA2 mutant mice [3]. Studies have also shown that 7q22 deletions are implicated in
playing a strong haploinsufficiency role in leukemogenesis [3]. Mutations in DOCK4 gene
which is a putative 7q gene have been identified in prostate and ovarian cancers and studies
have demonstrated that DOCK4 gene acts as a tumor suppressor [62]. Depletion of DOCK4
levels in MDS stem and progenitor cells leads to erythroid dysplasia by disrupting the action
of cytoskeleton in developing red blood cells (RBCs) ultimately leading to dysplastic mor‐
phology of erythroid cells both in vivo and in vitro [62].
7. Monosomy 7 MDS
Monosomy 7 is characterized by (1) lower median age of affected patients than that of 5q-
syndrome, (2) severe refractory cytopenias, (3) rapid disease progression, (4) resistance to
therapy, and (5) increased susceptibility to infectious complications [52, 63]. Infections
encountered in monosomy 7 may be life-threatening and they include (1) bacterial infections:
these are the most common types of infections and may be complicated by sepsis, and (2)
invasive aspergillosis [63, 64]. Infectious complications in monosomy 7 are caused by neutro‐
penia, dysfunctional neutrophils, and chemotherapy or targeted therapy given to control the
disease [64].
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In patients having monosomy 7, isolated monosomy 7 occurs in 36% of the cases, monosomy
7 and one additional chromosomal abnormality are encountered in 14% of patients, and
monosomy 7 associated with complex cytogenetics in seen in approximately 50% of the cases
[63]. Monosomy 7 can be associated with the following chromosomal abnormalities: trisomy
8, chromosome 5 abnormalities, and t(1,7) [63]. Chromosomal microarray analysis is a clinically
useful tool in the diagnosis and follow-up of MDS patients with monosomy 7 [65]. In monos‐
omy 7, there is an association between DNA loss and functional impairment or defect of
granulocytes [66]. Monosomy 7 is not rare in acute lymphoblastic leukemia as it has been
reported in 3–6% of the cases of ALL and in 16% of Philadelphia chromosome positive ALL
as it occurs as a secondary anomaly to t(9,22) [52]. Monosomy 7 carries poor prognosis as
studies have shown that (1) relapse rate of monosomy 7 at 1 year to be 81%, and (2) event-free
survival at 7 years to be 6% [52]. Monosomy 7 does not usually affect lymphoid subpopulations
but it is restricted to committed progenitor cells with the capacity to differentiate into mature
myeloid cells [67].
Analysis of expression profiles in CD34+ cells from MDS patients with monosomy 7 has shown
a malignant phenotype with highly proliferative potential expressing HOX9A, PRAME,
BMI-1, PLAB, and BRCA2 (DNA repair gene) [63]. Gene therapy for chronic granulomatous
disease has been reported to cause activation of ectopic viral integration site 1 (EVI1) which in
turn induces development of genomic instability that ultimately results in clonal progression
toward myelodysplasia and monosomy 7 [68].
Conventional chemotherapy in monosomy 7 carries a high risk of early death and poor
response. Even if complete remissions are obtained, they are usually short-lived [63]. Targeted
therapies such as 5-azacytidine and lenalidomide are more effective than cytotoxic chemo‐
therapy in patients with monosomy 7 MDS. However, lenalidomide is more effective in
patients having monosomy 7 and 5q- syndrome. Complete hematological and even cytogenetic
responses have been documented in patients with monosomy 7 MDS treated with lenalido‐
mide [63].
In transplant-eligible patients, allogeneic HSCT is the treatment of choice in patients with
monosomy 7 [25, 63, 69]. Following allogeneic HSCT, presence of monosomy 7 is a predictor
of unfavorable outcome [52].
Masked monosomy 7 refers to monosomy 7 that is detected by FISH but not by conventional
cytogenetics. It has been reported in varying frequencies in patients with MDS [70]. Masked
monosomy 7 is less common than has been thought and does not seem to carry the same
prognostic weight as monosomy 7 diagnosed by metaphase cytogenetics [70].
7.1. Monosomy 7 in children
MDS is uncommon in children as it accounts for less than 5% of all hematopoietic neoplasms
[33, 71]. Viral infections including Epstein-Barr virus (EBV) may contribute to the pathogenesis
of MDS by stimulating a preexisting clone and may induce certain genetic mutations [33].
Chromosome 7 abnormalities, monosomy 7 and del (7q), are common cytogenetic abnormal‐
ities in MDS and they are found in 31% of children with myeloid neoplasms [22, 71]. They are
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characterized by ineffective erythropoiesis, BM dysplasia, and increased risk of leukemic
transformation [22]. Monosomy 7 is the most common chromosomal abnormality in children
with MDS [33, 71]. In children, monosomy 7 implies poor prognosis because it is associated
with high risk of transformation into acute leukemia including ALL [33, 71].
Treatment of children with MDS/AML associated with monosomy 7 with allogeneic HSCT,
using a variety of donor types such as sibling donor, unrelated donor, and umbilical cord
blood, as well as different sources such as BM and peripheral blood, is an effective therapeutic
modality [69]. In patients with more advanced disease, optimization of conditioning therapies
may further improve disease-free survival [69]. Graft versus leukemia effect appears to play
a major role in leukemia control for some patients and quality of life (QOL) in patients
surviving allogeneic HSCT is usually very good [69].
7.2. Familial monosomy 7 syndrome
Familial monosomy 7 syndrome is a rare familial disorder [44, 45]. It is inherited as autosomal
dominant with incomplete penetrance [45]. Familial monosomy 7 can be partial or complete
monosomy and it is associated with the following chromosomal abnormalities: trisomy 8, 5q-,
and t(1;7) [45]. It has even sex distribution and often presents before the age of 18 years and
the median age at diagnosis in 8 years [45]. Allogeneic HSCT in this category of MDS is
problematic due to familial predisposition to cancer, hence the prognosis is usually poor [44,
45]. Familial monosomy 7 has several associations including: (1) inherited BM failure syn‐
dromes, (2) secondary MDS/AML, (3) occupational exposure to chemical toxins, (4) exposure
to cytotoxic chemotherapy, particularly alkylating agents, (5) Noonan syndrome, (6) Fanconi
anemia, and (7) cerebellar ataxia [44, 45]. The cell origin or phenotype is multipotential
progenitor cell [45]. The clinical manifestations of familial monosomy 7 syndrome include
complications of cytopenias, dysplasia, and acute leukemic transformation in addition to
features of the associated disease conditions [44, 45].
7.3. JMML
JMML is a rare clonal MDS/myeloproliferative neoplasm (MPN) of young children [44, 45, 72,
73]. It has also been described as juvenile CML and was formerly grouped in the French-
American-British (FAB) classification of MDS [74]. Without treatment, the 10-year overall
survival (OS) of patients with JMML is 6% [74]. Allogeneic HSCT is the only curative therapy
for children with JMML [72, 74]. Studies have also shown that event-free survival is 52% at 5
years post-HSCT [72]. Also, relapse is expected to occur in 50% of transplanted patients [72,
73]. Treatment options of relapsed JMML after the first HSCT include: (1) withdrawal of
immunosuppressive therapy and/or donor lymphocyte infusion, and (2) second allogeneic
HSCT, which may be the treatment of choice in such situations [72]. The major causes of HSCT
failure in patients with JMML are treatment-related mortality and relapse [74].
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8. Anemia in MDS
Severe anemia should be considered a major criterion for deciding not only the type but also
the timing of therapeutic interventions in patients with MDS [75]. Once anemia is symptomatic,
transfusion of packed RBCs is the mainstay of therapy in MDS [76]. The redistribution of
transfusion iron from reticuloendothelial cells to parenchymal cells is modulated by hepcidin.
Ineffective erythropoiesis has a suppressive effect on hepcidin production and hence increases
iron redistribution [76].
9. Iron overload in high-risk MDS
Transfusion history should be considered in transplantation decision making in patients with
MDS because pre-HSCT transfusion history and serum ferritin levels have been shown to have
significant prognostic value in patients with MDS undergoing allogeneic HSCT [77]. Elevated
serum ferritin and elevated liver iron content in patients with MDS and acute leukemia prior
to HSCT are associated with inferior post-HSCT survival [78]. Studies have shown that
transfusion dependency is independently associated with (1) reduced overall survival, (2)
increased nonrelapse mortality (NRM), and (3) increased risk of acute graft versus host disease
(GVHD) in patients with MDS undergoing allogeneic HSCT [77].
In patients with high-risk MDS, iron overload has adverse consequences on the outcome of
HSCT as it has been associated with (1) increased transfusion-related mortality, (2) infectious
complications, and (3) AML progression [79]. Iron chelation therapy in patients with higher
risk MDS should be considered to possibly (1) reduce infectious complications, (2) delay
leukemic transformation, and (3) improve the outcome of HSCT [80].
Nuclear factor-kappaB (NF-kB) is key regulator of many cellular processes and its impaired
activity has been described in different myeloid malignancies including MDS [81]. NF-kB
inhibition by deferasirox could prove to be an important therapeutic option in higher risk MDS
patients by targeting blast cells in which increased NF-kB activity has been extensively
demonstrated thus acting as a possible enhancer of chemosensitivity of the malignant clone
[81].
10. Management of MDS
The following therapeutic modalities are available for patients with MDS: (1) supportive
measures: packed RBCs and platelet (PLT) transfusions, antimicrobial therapy, and hemato‐
poietic growth factors, (2) drug therapies including novel agents such as lenalidomide,
azacytidine, and decitabine, and (3) various forms of HSCT [82].
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10.1. Epigenetic therapies of MDS
Epigenetic therapies cause potentially reversible epigenetic changes that can alter gene
expression patterns [83]. Epigenetic therapies in MDS include (1) histone deacetylase inhibi‐
tors, and (2) hypomethylating agents, such as azacytidine and decitabine, that inhibit the DNA
methyltransferase enzymes (DNMT) [83].
Epigenetic silencing is a universal mechanism of gene inactivation in malignant cells, probably
exceeding mutational events. Recent therapeutic approaches targeting the aberrant epigenome
of cancer has been developed [84]. The hypomethylating agents, azacytidine and decitabine,
have shown remarkable activity in older individuals with higher risk MDSs including patients
with poor-risk cytogenetic profiles. Translational studies performed on BM biopsies obtained
from MDS patients with both azanucleoside demethylating agents have indicated that both
azanucleosides can revert the aberrant hypermethylation state in vivo [84].
10.2. Hypomethylating agents
The azanucleosides, 5-azacytidine and decitabine, were originally synthesized more than 50
years ago in order to be used as classical cytotoxic agents [85–88]. Azacytidine was first
described by Sorm in 1964 as a cancerostatic agent [89]. Both hypomethylating agents, 5-
azacytidine and decitabine, had demonstrated activity against lymphoid leukemic cells as well
as hemopoietic tissues in experimental leukemia mice models [90–93].
10.2.1. 5-Azacytidine
Azacytidine is a pyrimidine nucleoside analog that differs from cytosine by the presence of
nitrogen, rather than ring carbon, at position 5 [8, 9]. It was first manufactured in Europe in
the 1960s [8, 9]. Azacytidine is a DNA methyltransferase inhibitor (DMTI) that has in vitro and
in vivo demethylating effects [9]. The hypomethylating effects of azacytidine appear to
primarily depend on the structural alternations at position 5 [8]. Azacytidine was the first
hypomethylating agent to be approved by the Food and Drug Administration (FDA) in United
States of America for the treatment of all subtypes of MDS in May 2009 [8, 10, 94]. In patients
with high-risk MDS, the benefits of azacytidine therapy on survival compared to conventional
chemotherapy have not been established outside clinical trials [95, 96]. Despite the wide spread
use of azacytidine in the treatment of high-risk MDSs, there is lack of improvement in long-
term survival. Therefore, identification of predicting factors of response and survival is
mandatory [95, 96].
Hypomethylating agents or azanucleosides are becoming the standard therapy for patients
with higher-risk MDSs [97]. Patients with high-risk MDSs treated with azanucleosides have a
median overall survival of 11–16 months, so they should be strongly considered for upfront
allogeneic HSCT or experimental therapies [97]. In patients with high-risk MDSs planned for
allogeneic HSCT, azacytidine treatment may be valuable in stabilizing the disease and
preventing relapse [98]. Additionally, pretransplant administration of azacytidine does not
adversely affect transplant outcome [98]. Preemptive azacytidine therapy has an acceptable
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safety profile and can substantially prevent or at least delay relapse in patients with MDS or
AML with minimal residual disease after allogeneic HSCT [99].
Name of trial CALG-B/8421 trial CALG-B/8921 trial
Phase Phase I Phase II
Azacytidine therapy IV administration
Initial dose: 75 mg/m2 continuous IV infusion over 7 days
every 28 daysdose escalated to 150 mg/m2
SC administration
100 mg/m2
Number of patients evaluated 43 68
Complete response 5 patients (12%) 8 patients (12%)
Partial response 11 patients (25%) 10 patients (15%)
Improvement 5 patients (12%) 18 patients (27%)
Total response 21 Patients (49%) 36 patients (53%)
Abbreviations: MDS, myelodysplastic syndrome; IV, intravenous; CALG-B, cancer and leukemia group B; SC,
subcutaneous.
Table 3. Phase I and phase II CALG-B clinical trials on azacytidine in MDS.
The outcome of patients with high-risk MDSs after failure of azacytidine treatment is generally
poor [100]. After failure of azacytidine treatment, the options are rather limited to (1) best
supportive care in patients unfit for allogeneic HSCT, and (2) allogeneic HSCT and investiga‐
tional agents in patients who are eligible for such therapies [100]. Mechanisms of action of 5-
azacytidine are multifactorial and they include (1) demethylation of several key genes, that is,
reduction of DNA methylation by inhibition of methyltransferase enzymes, (2) cytotoxic action
by inhibition of protein translation, and (3) enhancement of apoptosis [8–10]. In patients with
MDSs, 5-azacytodine is indicated in (1) high-risk MDSs, and (2) intermediate 2 risk MDSs [8,
10, 95, 97, 100–102]. The side effects of azacytidine therapy include myelosuppression (leuco‐
penia, anemia, and thrombocytopenia); gastrointestinal (GIT) upset (nausea, vomiting,
diarrhea, and constipation); injection site reactions and erythema; serum sickness-like illness;
abnormal liver function tests; fatigue; weakness; lethargy; anorexia; headache; arthralgias;
febrile neutropenia; cytomegalovirus infection; and pneumonia [9, 10, 99, 101, 103].
The effects of azacytidine in patients with MDSs include (1) prolongation of survival, (2)
improvement in QOL, and (3) delayed leukemic transformation [8, 10, 95, 101, 102]. Responses
to azacytidine according to karyotypes are as follows: (1) excellent responses are expected in
patients with normal cytogenetics, (2) durable remission and 80% response rate are expected
in patients having chromosome 7 abnormalities as the sole karyotypic abnormalities, and (3)
good early responses but early relapses in patients with trisomy 8 [9]. Predictors of positive
responses to DMTIs is include (1) doubling of PLT count, (2) mutated TET2, (3) mutated EZH2,
(4) Phosphoinositide-phospholipase C beta hypomethylation, and (5) low serum level of
micro-RNA-21 [96, 104, 105]. Predictors of poor response to DMTIs include (1) BM blasts >15%,
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(2) previous therapy, (3) transfusion dependency, (4) grade 3 marrow fibrosis, (5) mutated p53,
(6) abnormal karyotype of complex cytogenetics, (7) high serum level of micro-RNA-21, and
(8) increased cytidine deaminase expression of activity in males [96, 104, 106].
Trial AZA-001 trial CALG-B 9221 trial
Phase Phase III randomized controlled multicenter
international study
Phase III randomized controlled study
Study design Azacytidine Conventional care P-value Azacytidine Best supportive
care 
P-value   
   
Number of patients 179 179 – 99 92 –
IPSS class
intermediate
2 and high risk
158 patients (89%) 155 patients (87%) – 20% 26% –
Median survival
(months)
24.5 months 15 months ≤0.0001 18 months 11 months 0.03
2 year overall
survival
50.8% 26.2% <0.0001 – – –
Transformation to
AML
15% 38% 0.001
Median time to AML
transformation
17.8 months 11.5 months ≤0.0001 21 months 13 months 0.007
Complete response 30 patients (17%) 14 patients (4%) 0.015 7% 0% 0.01
Partial response 21 patients (12%) 7 patients (4%) 0.0094 16% 0% <0.0001
Improvement Stable disease 75
patients (42%)
Stable disease 65
patients (36%)
0.33 37% 5% <0.0001
Overall response HI in 87 patients
(49%)
HI in 51 patients
(29%)
60% 5% -
Abbreviations: MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; IPSS, International Prognostic Scoring
System; CALG-B, cancer and leukemia group B; AZA, azacytidine HI: hematological improvement.
Table 4. Phase III randomized controlled clinical trials on azacytidine.
In patients with high-risk MDSs and AML, the combination of 5-azacytidine, valproic acid,
and all-trans retinoic acid (ATRA) are safe and they are active and associated with induc‐
tion of global DNA hypomethylation and histone acetylation [107, 108]. Lessons learned from
clinical experience with hypomethylating agents include (1) in the majority of treated
patients, the beneficial effects are only noted after approximately four cycles of therapy, (2)
the achievement of hematological improvement is sufficient to ensure prolonged OS, (3) in
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almost all patients, interruption of treatment induces relapse, (4) patients who relapse after
treatment or who are refractory to therapy have extremely limited survival, and (5) pa‐
tients with complex karyotype involving monosomy 7 or monosomy 5 have negligible
survival advantage from hypomethylating agents despite achievement of response [96].
Clinical phase I, II, and III trials on the use of azacytidine in patients with MDSs are shown
in Tables 3 and 4 [9, 10, 101, 103, 109]. Investigational agents that can be used in the treatment
of MDSs in case of failure of hypomethylating agents include (1) rigosertib, (2) sapacita‐
bine, (3) clofarabine, and (4) BCL2 inhibitors (proapoptotic drug therapy) including ABT-737
and ABT-199 [96, 110].
Conclusion that can be drawn from phase III trials on azacytidine include: (1) in CALG-B 9221
trial: compared to best supportive care (BSC), azacytidine therapy resulted in (a) significantly
higher response rates, (b) improved QOL, (c) improved survival, and (d) reduced risk of
leukemic transformation; and (2) in AZA-001 trial: compared to conventional therapy, that
Included BSC, low dose cytarabine ± intensive chemotherapy, azacytidine increased OS in
patients with high-risk MDS [101, 109]. In patients with chromosome 7 abnormalities [mon‐
osomy 7 and del(7q)], the median survival was 13.1 months in patients treated with azacytidine
compared to 4.6 months in patients who received conventional therapies [101].
10.2.2. Decitabine
Decitabine (5-aza-2-deoxycytidine) inhibits DNMT. It was approved by the FDA in the United
States for the treatment of MDS in the year 2006 [83, 111, 112]. It is postulated that initially the
drug and the DNMT enzymes become attached, then the outcome will be: (1) enzyme degra‐
dation resulting in low DNMT levels, and (2) ultimately achievement of hypomethylation [83].
Although decitabine antitumor activity is not fully understood, there are several possible
mechanisms of action that include (1) induction of hypomethylation or reversal of cancer-
associated hypermethylation effects, (2) reactivation of genes responsible for cellular differ‐
entiation, (3) stimulation or induction of immune responses, (4) induction of DNA damage
pathways or apoptotic response pathways, that is, induction of changes in the rates of
apoptosis, and (5) augmentation of stem cell renewal [83, 105]. Various doses, schedules, and
even routes of administration have been used: 10, 15, or 20 mg/m2 intravenously (IV) or
subcutaneously (SC) for 3–5 days, each cycle for at least four cycles that are given at 4- to 6-
week intervals [83, 111, 112].
Although it has been used in the treatment of all FAB subtypes of MDS, the specific indications
are as follows: (1) intermediate 1, intermediate 2, and high-risk MDS, (2) de novo and secondary
MDS, including t-MDS, (3) MDS transforming into AML, in individuals unfit for intensive
cytotoxic chemotherapy, as upfront therapy, (4) treatment of MDS refractory to lenalidomide,
(5) debulking treatment prior to HSCT in high-risk patients, and (6) patients with chronic
myelomonocytic leukemia (CMML) [83, 105, 111]. The adverse effects of decitabine therapy
include (1) myelosuppression leading to febrile neutropenia, sepsis, pneumonia, and fungal
infections, (2) gastrointestinal effects including nausea, vomiting, diarrhea, and mucositis, (3)
hair loss, skin rashes, fatigue, and bleeding, (4) renal failure, (5) cardiovascular complications
are uncommon, and (6) pleural effusions and acute lung injury [83, 112, 113]. Encountering
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myelosuppression that requires decitabine dose modification may truly indicate response to
therapy [112].
Despite the efficacy of dectiabine therapy, there are no known definitive predictors of response.
However, in patients with high-risk MDS treated with decitabine, high expression of human
equilibrative nucleoside transporter-1 (hENT-1) gene appears to predict a good response to
decitabine therapy and is associated with prolonged survival [114]. Patients with chromosome
7 abnormalities usually respond more favorably to continuous IV infusion of low-dose
decitabine than to conventional chemotherapy with low-dose cytarabine [115]. Results of
clinical trials on decitabine are shown in Table 5 [83, 84, 111, 113]. Unfortunately, there is no
head-to-head comparison with 5-azacytidine. Also, decitabine has not shown a statistically
significant evidence of prolonged survival benefit in prospective studies. In addition, the role
of decitabine after HSCT needs further evaluation [83].
10.2.3. Rigosertib (ON01910.Na)
Rigosertib is a multikinase inhibitor that inhibits both the phosphoinositide 3 kinase and the
polo-like kinase pathways [116–120]. It inhibits the cell-cycle progression by selectively
inducing a mitotic arrest and apoptosis in cancer cells [116, 118–120]. Recently, it has been
highlighted as a novel anticancer agent for the treatment of MDS. Rigosertib has shown activity
in the following malignancies: (1) mantle cell lymphoma, (2) chronic lymphocytic leukemia,
and (3) MDS [118]. In MDS, rigosertib has several mechanisms of action that include: (a)
upregulation of genes related to microtubule kinetics, (b) downregulation of the mRNA
degradation system, that is, suppression of nonsense mRNA decay (NMD) gene, (c) suppres‐
sion of cyclin-D1 in BM CD34+ cells in MDS patients with trisomy 8 and monosomy 7, and (d)
induction of cell death by inhibition of PI3kinase/Akt pathway and DNA damage-induced G2/
M arrest, that is, induction of mitotic arrest and apoptosis in myeloblasts while sparing normal
cells [118–120].
Rigosetib has shown efficacy in all morphologic, prognostic risk and cytogenetic subgroups
of MDS and has produced complete responses in some patients [121]. It has shown activity in
high-risk MDS patients and in those having monosomy 7 and trisomy 8. It has produced the
following beneficial effects: (1) decrease in BM blasts, (2) improvement in hematopoiesis, (3)
inhibition of cyclin D1 accumulation, and (4) decrease in trisomy 8 and monosomy 7 aneu‐
ploidy [116, 119, 121]. However, a randomized controlled, phase 3, clinical trial that had been
performed in 74 institutions in Europe and the United States on the use of rigosertib in patients
with high-risk MDS after failure of hypomethylating agents did not show significant OS
compared to best supportive care [117]. The drug is available in oral and injectable formula‐
tions [120, 121]. Although rigosertib has exhibited a favorable safety profile, the following
adverse effects have been reported: syncope, fatigue, nausea, vomiting, abdominal pain,
hypotension, anemia, thrombocytopenia, neutropenia, febrile neuropenia, pneumonia,
dysuria, and hematuria [116, 117, 120].
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Trial Number
of
patients 
Phase and
design of trial
Study focus Results Total
dose per
course/
interval
between
cycles
Median
number
of
courses
Time to
AML
progress
Median
survival
Kantarjian et
al. Cancer
2006
170 Phase II
randomized
multicenter
Decitabine vs.
BSC
OR: 17%
CR: 9%
PR: 8%
HI: 13%
135 mg/m2
6 weekly
3 12.1
months
vs. 7.8
months
14
months
vs. 14.9
months
Ruter et al.
Cancer 2006
22 Phase II
pooled
analysis of 3
trials
Low dose
decitabine as
salvage therapy
at relapse
OR: 45%
CR: 4.5%
PR: 9.1%
HI: 31.8%
135 mg/m2
6 weekly
3 - 37.5
months
Kantarjian et
al. Cancer
2007
115 Phase II
1 single center
Prognostic
factors
associated with
outcome
OR: 70%
CR: 35%
PR: 2%
HI: 10–23%
100 mg/m2
4 weekly
≥7 Not
reached
22
months
Kantarjian et
al. Blood 2007
95 Phase II
randomized
single center
Optimal dosage
of decitabine
OR: 73%
CR: 34–39%
PR: 1%
HI: 14–24%
100 mg/m2
-
≥6 27% over
18
months
19
months
Kantarjian et
al. Cancer
2007
491 Phase II
historical
comparison of
2 groups of
patients at
single center
Decitabine vs.
AML type of
intensive
chemotherapy
CR: decit: 43% vs.
intensive
chemotherapy:
34%
100 mg/m2
–
– – 22
months
vs. 12
months
Borthakur et
al. Leuk
Lymphoma
2008
14 Phase II early
results
Efficacy of
decitabine after
failure of vidaza
OR: 28%
CR: 21%
HI: 7%
100 mg/m2
4 weekly
3 4 months 6 months
Steensma et
al. JCO 2009
99 Phase II
multicenter
non
randomized
Efficacy & safety
of decitabine as
outpatient
regimen
OR: 32%
CR: 17%
HI: 18%
100 mg/m2
4 weekly
5 – 19.4
months
Lubbert et al.
JCO 2011
233 Phase III- 2
arms
multicenter
Decitabine vs.
BSC
CR: 13%
PR: 6%
HI: 15%
95 mg/m2
6 weekly
4 8.8
months
vs.
6.1
months
PFS: 6.6
months
vs. 3
months
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Trial Number
of
patients 
Phase and
design of trial
Study focus Results Total
dose per
course/
interval
between
cycles
Median
number
of
courses
Time to
AML
progress
Median
survival
Jabbour et al.
Clin
Lymphoma
Myeloma
Leuk 2013
183 Phase III
pooled
analysis of 2
multicenter
trials
Decitabine vs.
BSC in de novo
MDS vs. 20
MDS
OR: 28% de novo
MDS vs. 15.4% in
20 MDS
135 mg/m2
4–6 weekly
3 and 5
courses
33
months
for 2°
MDS
not
reached
for de novo
MDS
OS: 16.6
months
vs.
9 months
Abbreviations: MDS, myelodysplastic syndrome; AML, acute myeloid leukemia; OR, overall response; CR, complete
response; PR, partial response; HI, hematological improvement; BSC, best supportive care; vs., versus; 20, secondary;
OS, overall survival.
Table 5. Decitabine trials in MDS patients.
11. The role of HSCT in high-risk MDSs including monosomy 7
11.1. HSCT in adults with MDSs
Allogeneic HSCT is the only potentially curative therapy for MDS patients [4, 82, 122–124].
Recently, HSCT is being used with increasing frequency in patients with MDS, partly due to
the development of novel conditioning therapies, such as nonmyeloablative conditioning, that
allow HSCT to be offered to older patients [4, 122]. Also, the use of immunomodulatory drugs
and hypomethylating agents prior to HSCT has shown efficacy in (1) controlling disease, that
is, a bridging approach to HSCT, and (2) tumor debulking before HSCT [4, 122]. The indications
of allogeneic HSCT in adults with MDS are shown in Table 6 [4, 82, 122–125].
MDS patients with monosomy 7 or complex cytogenetics and preserved BM are considered
indications for immediate rather than delayed HSCT. Secondary MDS is another special
indication for HSCT [82, 125]. Currently, patients with therapy-related MDS (t-MDS) are being
treated using the same paradigm as in de novo MDS [82]. Despite its curative potential, the role
of allogeneic HSCT in the treatment of elderly patients with MDS is less well defined than in
younger individuals [4]. The following issues related to HSCT remain an area of intense
investigations: (1) pretransplant disease burden, (2) optimal conditioning therapies, (3)
optimal donor selection, (4) optimal stem cell source, (5) GVHD prophylaxis, and (6) post‐
transplant relapse [122]. The following complications of allogeneic HSCT: GVHD, infections,
and non-relapse mortality may offset the benefits of allogeneic HSCT over medical therapies
[82]. Despite the remarkable improvement in both efficacy and safety of HSCT over the past
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two decades, therapy-related morbidity and mortality as well as disease relapse still pose
significant risks to transplanted patients [82, 122, 123]. Methods employed to prevent and treat
relapse of MDS following HSCT include (1) donor lymphocyte infusion (DLI), (2) hypome‐
thylating agents, (3) novel cellular therapies including vaccination, and (4) use of alloreactive
natural killer cells [4, 122].
In children In adults
1- Refractory anemia with excess of blasts
(RAEB)
2- Refractory anemia with excess of blasts in
transformation (RAEB-t)
3- Chemotherapy or radiotherapy related MDS
(t-MDS)
4- Juvenile myelomonocytic leukemia
5- Refractory cytopenias associated with:
a- transfusion dependence
b- cytogenetic abnormalities
(A) Definite indications:
1- Intermediate 2 IPSS
2- High-risk IPSS
(B) Probable indications:
1- t-MDS or secondary MDS
2- Packed Red blood cell transfusions refractory to:
- Hematopoietic growth factors
- Immunomodulatory drugs
- Hypomethylating agents
3- Severe neutropenia or thrombocytopenia
4- At least one line of cytopenia with multilineage dysplasia
5- High risk chromosomal abnormalities: monosomy 7 and complex
cytogenetics
6- High percentage of blasts [≥10%]
Abbreviations: MDS, myelodysplastic syndrome; t-MDS, therapy-related myelodysplastic syndrome; RAEB, refractory
anemia with excess of blasts; RAEB-t, refractory anemia with excess of blasts in transformation; SCT, hematopoietic
stem cell transplantation.
Table 6. Indications for allogeneic HSCT in patients with MDS.
Predictors of outcome of allogeneic HSCT in MDS patients include: (1) disease stage including
blast count, (2) transfusion dependence, and (3) karyotype, cytogenetic abnormalities and
molecular aberrations or genetic mutations such as: monosomal karyotype, complex cytoge‐
netic and TP53 mutation [82, 122, 125].
11.2. HSCT in children with MDSs
Allogeneic HSCT is the only potentially curative therapy for children with MDSs, particularly
those having JMML [73, 126]. The indications of allogeneic HSCT in children with MDSs are
shown in Table 6 [73, 126–128]. Relapse rate following allogeneic HSCT performed for JMML
may reach 50% or more [73]. Children with MDS and JMML should be referred for allogeneic
HSCT soon after making the diagnosis in order to prevent disease progression as pretransplant
chemotherapy does not appear to improve outcome [127, 128]. Predictors of poor outcome of
allogeneic HSCT in children with MDS include (1) monosomy 7, (2) age more than 4 years at
transplant, (3) relapse after HSCT, (4) female gender, and (5) human leukocyte antigen (HLA)-
mismatched allografts [73].
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11.3. HSCT in higher risk MDS patients
Patients with higher risk MDS who have an HLA-matched donor should be transplanted early
before progression of their disease or acquisition of a nonhematological contraindication to
HSCT [129]. In patients with intermediate-2 or high-risk MDS, aged 60–79 years, subjected to
reduced intensity conditioning allogeneic HSCT, life expectancy is about 36 months compared
to 28 months in patients not subjected to HSCT, that is, HSCT in this group of patients has a
survival advantage [130]. Patients with higher risk MDS should be treated with either
hypomethylating agents or HSCT [131]. It is justified to offer patients with higher risk MDS
who have an HLA identical donor an allograft [129]. Retrospective studies have concluded
that patients with higher risk MDS have a survival advantage over demethylating agents if
they can be offered an early allogeneic HSCT [129]. Transplant-related mortality remains high
in HSCT, it ranges between 10% and 40% particularly after myeloablative conditioning therapy
in elderly individuals [129]. Long-term survival ranges between 30% and 60% depending on
patient characteristics, disease risk, type of donor, source of stem cells, and complications that
evolve following HSCT [129].
12. Conclusions and future directions
In children and adults, high-risk MDSs including monosomy 7 are often complicated by
various degrees of BM suppression, infectious complications, severe iron overload, and
transformation into AML. Management of these disorders includes (1) supportive care that
comprises transfusion of blood products, antimicrobials, and iron chelation therapy, (2)
epigenetic therapies including histone deacetylase inhibitors and hypomethylating agents
such as azacytidine and decitabine, and (3) various types of allogeneic HSCT. Recently, the
role of allogeneic HSCT in high-risk MDSs is increasing due to the introduction of the new
conditioning therapies that have allowed the application of this curative modality of therapy
not only to older patients, but also to individuals with medical comorbidities. However, in
patients with familial causes of their MDSs of BM failure planned for allogeneic HSCT using
a sibling donor, great caution should be exercised and enough investigations should be
performed before clearing the sibling for donation. The role of certain growth factors in the
management of patients with high-risk MDS is controversial as G-CSF has been reported to
accelerate the progression into acute leukemia.
The recent developments in the diagnostics of MDSs and the recently introduced therapeutic
agents such as rigosertib, clofarabine, sapacitabine, and BCL2 inhibitors as well as the evolving
modalities of HSCT are likely to improve the outcome of patients with higher risk MDSs
significantly.
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